Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Drug Anaphylaxis Clear all

Active, not recruiting No phase listed Observational

Cause of Unexplained Anaphylaxis

NCT00719719

View directory record Official record

Conditions: Idiopathic Anaphylaxis, Drug Anaphylaxis, Venom Anaphylaxis, Food Anaphylaxis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 75 Years

Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Apr 30, 2026 · Synced May 22, 2026, 1:12 AM EDT

Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

NCT04207840

View directory record Official record

Conditions: Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions: Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation); Combination Product
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Mar 29, 2021 · Synced May 22, 2026, 1:12 AM EDT

Recruiting Phase 2 Interventional

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

NCT06406114

View directory record Official record

Conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years

Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Mar 18, 2026 · Synced May 22, 2026, 1:12 AM EDT